In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Innovation

Set Alert for Innovation

Funding The Future: Accelerating The Long Walk To Innovation

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.

New Science StartUps and SMEs

Snapshot: June Highlights

A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.

New Science Market Intelligence

Pharma Spreads Its Bets On Multiple Modalities In Advanced Products

Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.

Gene Therapy Research & Development

What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.

New Science Leadership

How Viable Is The Future Of The “Traditional” CGM?

Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.

New Science Diabetic Care

Israel’s Authority On Medical Robotics Lifts Curtain Behind Technion’s Success Stories

Moshe Shoham talks about the innovative technologies behind surgical robotics companies Microbot Medical, XACT Robotics, Tamar Robotics and ForSight Robotics, which were all spun out of his laboratory in Israel.

Robotic Surgery New Science

The Biopharma A List: Taking The Pulse Of Newco Creation

The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.

StartUps and SMEs Financing

Juicy Apples Come From Healthy Trees: Advice For Platform Developers

Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.

Innovation Platform Technologies

Trust And Talent In A Start-Up: A Two-Way Street

Rutger Zietsma, founder of Manus Neurodynamica and one of In Vivo's Rising Leaders of 2022, explains how his prior work guided his journey into executorship, and the issues of trust and talent in a start-up environment. 

Neurology Innovation

FDA Leader: We Need To Remove Surprises From Gene Therapy Development

Embattled gene therapy companies will take comfort from desire of FDA and EMA help smooth the process of bringing the novel treatments to market.

New Science Gene Therapy

Partnerships Picks For GeNeuro’s MS Antibody

The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.

New Science Research & Development

Advanced Antibodies Will Revolutionize The Future Of IO

Immuno-oncology is a key area for biological drug development and activity has exploded over the past decade. Today, IO therapies represent a third of the biologics pipeline, and antibody development remains the focus.

Cancer Innovation
See All
UsernamePublicRestriction

Register